Sep 20, Green Roads: Second Summary. Green Roads has a lot going for them, including a claimed 1,,+ end users of their products, which. Sep 26, Green Garden Gold: Second Summary. Green Garden Gold offers a wide variety of products for the everyday CBD consumer, including. Nov 1, Green Roads of Florida LLC 10/31/17 “CBD Edibles Gummie Blocks 60mg”, “ CBD Edibles Jollies 30mg”, “CBD Edibles Gummie Men 60mg”.
60-Second Green Summary Roads:
Emmanuel Foster May 16, Adrienne Crass May 14, Tried the green roads oil recently for my chronic cough yesterday, lets see how it works. So far I think taste is great. Hope this works because the cough syrups made me drowsy and didn't work.
Tamika Oliveira May 13, I was seeking a good quality CBD terp oil which did not taste horrible. I am currently running on my second bottle. It dissolves quickly under the tongue. Katy May 12, I will be buying from them! Gary Dean May 10, A glass bottle sliced open my hand and did some good nerve damage. Have been using pain Cream on it. Really glad I tried it. David Peebles May 9, As a cancer patient for last 8 months, I will give anything to increase the chances of my survival.
Have been going through chemo and meds daily had drained me out. The worst thing about these treatment is pain and depression. I often suffer from mood swing which tends to affect my social life. Cannabidiol oil has been very helpful whenever I felt lightheaded and nauseous I took one drop of it and felt better after a while. Emma White May 8, Bought this for my furry cat.
She used to barf all over the floor in anxiety and was extra feisty. Keely Armstrong April 18, I just tried Green Roads for the first time and yes it did help the arthritic pain in my feet but I didn't feel it did as well as CW Capsules for my anxiety and depression.
I also don't like the taste or the texture. It is super thick and for me sublingually it isn't absorbed. The taste is a put off also Sue January 18, Green Roads is an amazing product, however their customer service and organization sucks. Megan January 16, Just to give everyone a little background I am 29 an was diagnosed with manic bipolar depressive disorder.
Severe anxiety, ADHD and degenerative disk disease. After years of trying different pharmaceuticals like Xanax, lamictal, adderall and Percocet it seemed as if nothing was ever going to help without making me a complete zombie or going into a rage and wanting to end my life I just felt hopeless. With no other options available a friend had suggested I try cbd and only after one dose of the mg I almost instantly could tell the cloud of doom that hung over my head an made me want to end my life was gone, along with the debilitating pain I faced everyday.
I will always give green roads credit for literally saving my life!!! Robyn Brown January 16, I have tried several brands at least 6 different ones greenroads world works best for me! I love the quality of the products too!
Good price, Great products! I love this company. I was looking for an alternative instead of taking pain pills all the time. I will keep ordering! Carina January 16, I was told about Green Roads world from a friend who was already using their products. I was on medication for anxiety and insomnia. I started using CBD and slowly but surely I was off the meds and have been off for over a year. I got family members to try out their CBD and they also love it. I will be a forever customer. EE December 10, In the Tampa, FL area, Greenroads appears to be stocked in almost every smoke shop.
It has worked as well as my comparable Nuleaf product so far for back and joint pain. Love the pain cream, as well as the mg sublingual. It's an amazing product I would suggest it to anyone. Joe October 5, We are both 65 and glad to have started this regimen Effect of etoricoxib on drugs metabolised by sulfotransferases.
Etoricoxib is an inhibitor of human sulfotransferase activity, particularly SULT1E1, and has been shown to increase the serum concentrations of ethinyl estradiol. While knowledge about effects of multiple sulfotransferases is presently limited and the clinical consequences for many drugs are still being examined, it may be prudent to exercise care when administering etoricoxib concurrently with other drugs primarily metabolised by human sulfotransferases e.
Effect of etoricoxib on drugs metabolised by CYP isoenzymes. In a study in healthy subjects, daily administration of etoricoxib mg did not alter hepatic CYP3A4 activity as assessed by the erythromycin breath test. Effects of other drugs on the pharmacokinetics of etoricoxib. The main pathway of etoricoxib metabolism is dependent on CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib in vivo. Co-administration of either oral voriconazole or topical miconazole oral gel, strong CYP3A4 inhibitors, with etoricoxib caused a slight increase in exposure to etoricoxib, but is not considered to be clinically meaningful based on published data.
This interaction may result in recurrence of symptoms when etoricoxib is co-administered with rifampicin. While this information may suggest an increase in dose, doses of etoricoxib greater than those listed for each indication have not been studied in combination with rifampicin and are therefore not recommended see section 4. Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant extent. No clinical data on exposed pregnancies are available for etoricoxib.
Studies in animals have shown reproductive toxicity see section 5. The potential for human risk in pregnancy is unknown. Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Etoricoxib is contraindicated in pregnancy see section 4. If a woman becomes pregnant during treatment, etoricoxib must be discontinued.
It is not known whether etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use etoricoxib must not breast feed see sections 4. The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive. In clinical trials, etoricoxib was evaluated for safety in 9, individuals, including 6, patients with OA, RA, chronic low back pain or ankylosing spondylitis approximately patients with OA or RA were treated for one year or longer.
In clinical studies, the undesirable effects profile was similar in patients with OA or RA treated with etoricoxib for one year or longer. In a clinical study for acute gouty arthritis, patients were treated with etoricoxib mg once daily for eight days.
The adverse experience profile in this study was generally similar to that reported in the combined OA, RA, and chronic low back pain studies. In a cardiovascular safety outcomes programme of pooled data from three active comparator controlled trials, 17, patients with OA or RA were treated with etoricoxib 60 mg or 90 mg for a mean duration of approximately 18 months.
The safety data and details from this programme are presented in section 5. In clinical studies for acute postoperative dental pain following surgery including patients treated with etoricoxib 90 mg or mg , the adverse experience profile in these studies was generally similar to that reported in the combined OA, RA, and chronic low back pain studies.
Tabulated list of adverse reactions. Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Its reported frequency has been estimated based upon the highest frequency observed across clinical trial data pooled by indication and approved dose. The following serious undesirable effects have been reported in association with the use of NSAIDs and cannot be ruled out for etoricoxib: Reporting of suspected adverse reactions.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: There have been reports of acute overdosage with etoricoxib, although adverse experiences were not reported in the majority of cases.
The most frequently observed adverse experiences were consistent with the safety profile for etoricoxib e. In the event of overdose, it is reasonable to employ the usual supportive measures, e. Etoricoxib is not dialysable by haemodialysis; it is not known whether etoricoxib is dialysable by peritoneal dialysis. Anti-inflammatory and antirheumatic products, non-steroids, coxibs, ATC code: M01 AH05 Mechanism of Action.
Etoricoxib is an oral, selective cyclo-oxygenase-2 COX-2 inhibitor within the clinical dose range. Etoricoxib did not inhibit gastric prostaglandin synthesis and had no effect on platelet function.
Cyclooxygenase is responsible for generation of prostaglandins. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions fever induction, pain perception and cognitive function.
It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established. Clinical efficacy and safety. In patients with osteoarthritis OA , etoricoxib 60 mg once daily provided significant improvements in pain and patient assessments of disease status.
These beneficial effects were observed as early as the second day of therapy and maintained for up to 52 weeks. Studies with etoricoxib 30 mg once daily demonstrated efficacy superior to placebo over a 12 week treatment period using similar assessments as the above studies. In a dose ranging study, etoricoxib 60 mg demonstrated significantly greater improvement than 30 mg for all 3 primary endpoints over 6 weeks of treatment.
The 30 mg dose has not been studied in osteoarthritis of hands. In patients with rheumatoid arthritis RA , etoricoxib 60 mg and 90 mg once daily both provided significant improvements in pain, inflammation, and mobility.
In studies evaluating the 60 mg and 90 mg dose, these beneficial effects were maintained over the week treatment periods. In a study evaluating the 60 mg dose compared to the 90 mg dose, etoricoxib 60 mg once daily and 90 mg once daily were both more effective than placebo. The 90 mg dose was superior to the 60 mg dose for Patient Global Assessment of Pain mm visual analogue scale , with an average improvement of In patients experiencing attacks of acute gouty arthritis, etoricoxib mg once daily over an eight-day treatment period, relieved moderate to extreme joint pain and inflammation comparable to indomethacin 50 mg three times daily.
Pain relief was observed as early as four hours after initiation of treatment. In patients with ankylosing spondylitis, etoricoxib 90 mg once daily provided significant improvements in spine pain, inflammation, stiffness and function. The clinical benefit of etoricoxib was observed as early as the second day of therapy after initiation of treatment and was maintained throughout the week treatment period. In a second study evaluating the 60 mg dose compared to the 90 mg dose, etoricoxib 60 mg daily and 90 mg daily demonstrated similar efficacy compared to naproxen 1, mg daily.
Among inadequate responders to 60 mg daily for 6 weeks, dose escalation to 90 mg daily improved spinal pain intensity score mm visual analogue scale compared to continuing on 60 mg daily, with an average improvement of In a clinical study evaluating postoperative dental pain, etoricoxib 90 mg was administered once daily for up to three days. In the subgroup of patients with moderate pain at baseline, etoricoxib 90 mg demonstrated a similar analgesic effect to that of ibuprofen mg The proportion of patients reporting rescue medication usage within the first 24 hours of dosing was In this study, the median onset of action perceptible pain relief of 90 mg etoricoxib was 28 minutes after dosing.
In this trial, only serious adverse events and discontinuations due to any adverse events were recorded. Patients enrolled in the Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline.
Patients with a recent history of myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within 6 months preceding enrollment were excluded. Use of gastroprotective agents and low dose aspirin were permitted in the studies.
There was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events. Cardiorenal adverse events were observed more frequently with etoricoxib than with diclofenac, and this effect was dose-dependent see specific results below. Gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib.
The rate of confirmed thrombotic cardiovascular serious adverse events consisting of cardiac, cerebrovascular, and peripheral vascular events was comparable between etoricoxib and diclofenac, and data are summarized in the table below.
There were no statistically significant differences in thrombotic event rates between etoricoxib and diclofenac across all subgroups analyzed including patient categories across a range of baseline cardiovascular risk. When considered separately, the relative risks for confirmed thrombotic cardiovascular serious adverse events with etoricoxib 60 mg or 90 mg compared with diclofenac mg were similar. CV mortality, as well as overall mortality, was similar between the etoricoxib and diclofenac treatment groups.
In the study, the incidence of discontinuations due to hypertension-related adverse events was statistically significantly higher for etoricoxib than for diclofenac. The incidence of congestive heart failure adverse events discontinuations and serious events occurred at similar rates on etoricoxib 60 mg compared to diclofenac mg but was higher for etoricoxib 90 mg compared to diclofenac mg statistically significant for 90 mg etoricoxib vs. The incidence of confirmed congestive heart failure adverse events events that were serious and resulted in hospitalisation or a visit to an emergency department was non-significantly higher with etoricoxib than diclofenac mg, and this effect was dose-dependent.
The incidence of discontinuations due to oedema-related adverse events was higher for etoricoxib than diclofenac mg, and this effect was dose-dependent statistically significant for etoricoxib 90 mg, but not for etoricoxib 60 mg. In the individual MEDAL Programme studies, for etoricoxib 60 mg or 90 mg , the absolute incidence of discontinuation in any treatment group was up to 2.
A significantly lower rate of discontinuations of treatment for any clinical e. The rates of discontinuations due to adverse clinical GI events per hundred patient-years over the entire period of study were as follows: Overall upper GI events were defined as perforations, ulcers and bleeds.
The subset of overall upper GI events considered complicated included perforations, obstructions, and complicated bleeding; the subset of upper GI events considered uncomplicated included uncomplicated bleeds and uncomplicated ulcers. A significantly lower rate of overall upper GI events was observed with etoricoxib compared to diclofenac. There was no significant difference between etoricoxib and diclofenac in the rate of complicated events.
For the subset of upper GI haemorrhage events complicated and uncomplicated combined , there was no significant difference between etoricoxib and diclofenac. The rates per hundred patient-years of confirmed complicated and uncomplicated upper GI clinical events perforations, ulcers and bleeds PUBs were 0.
The rates of confirmed lower GI clinical events small or large bowel perforation, obstruction, or haemorrhage, POBs were not significantly different between etoricoxib and diclofenac. Etoricoxib was associated with a statistically significantly lower rate of discontinuations due to hepatic-related adverse experiences than diclofenac.
The rate per hundred patient-years was 0. Additional Thrombotic Cardiovascular Safety Data. However, the rate of these events was higher in patients receiving etoricoxib compared with those receiving naproxen mg twice daily. Selective COX-2 inhibitors reduce the formation of systemic and therefore possibly endothelial prostacyclin without affecting platelet thromboxane.
The clinical relevance of these observations has not been established. Additional Gastrointestinal Safety Data. In two week double-blind endoscopy studies, the cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib mg once daily than in patients treated with either naproxen mg twice daily or ibuprofen mg three times daily.
Etoricoxib had a higher incidence of ulceration as compared to placebo. Renal Function Study in the Elderly. Etoricoxib, celecoxib, and naproxen had similar effects on urinary sodium excretion over the 2 weeks of treatment. All active comparators showed an increase relative to placebo with respect to systolic blood pressures; however, etoricoxib was associated with a statistically significant increase at Day 14 when compared to celecoxib and naproxen mean change from baseline for systolic blood pressure: Orally administered etoricoxib is well absorbed.
The geometric mean area under the curve AUC hr was The pharmacokinetics of etoricoxib are linear across the clinical dose range. Dosing with food a high-fat meal had no effect on the extent of absorption of etoricoxib after administration of a mg dose. These data are not considered clinically significant. In clinical trials, etoricoxib was administered without regard to food intake.
The volume of distribution at steady state V dss was approximately 1,20l in humans. Etoricoxib crosses the placenta in rats and rabbits, and the blood-brain barrier in rats. The major route of metabolism to form the 6'-hydroxymethyl derivative is catalyzed by CYP enzymes. Five metabolites have been identified in man. The principal metabolite is the 6'-carboxylic acid derivative of etoricoxib formed by further oxidation of the 6'-hydroxymethyl derivative. These principal metabolites either demonstrate no measurable activity or are only weakly active as COX-2 inhibitors.
None of these metabolites inhibit COX Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion. Steady state concentrations of etoricoxib are reached within seven days of once daily administration of mg, with an accumulation ratio of approximately 2, corresponding to a half-life of approximately 22 hours. Pharmacokinetics in the elderly 65 years of age and older are similar to those in the young.
The pharmacokinetics of etoricoxib are similar between men and women. Patients with moderate hepatic dysfunction Child-Pugh score administered etoricoxib 60 mg every other day had similar mean AUC to the healthy subjects given etoricoxib 60 mg once daily; etoricoxib 30 mg once daily has not been studied in this population. The pharmacokinetics of a single dose of etoricoxib mg in patients with moderate to severe renal insufficiency and patients with end-stage renal disease on haemodialysis were not significantly different from those in healthy subjects.
Safety and effectiveness of etoricoxib in paediatric patients have not been established see section 4. Etoricoxib was not carcinogenic in mice. Hepatocellular and thyroid follicular cell adenomas observed in rats are considered to be a consequence of rat-specific mechanism related to hepatic CYP enzyme induction.
Etoricoxib has not been shown to cause hepatic CYP3A enzyme induction in humans. In the rat, gastrointestinal toxicity of etoricoxib increased with dose and exposure time. In the week toxicity study etoricoxib caused gastrointestinal ulcers at exposures greater than those seen in man at the therapeutic dose.
In the and week toxicity study, gastrointestinal ulcers were also seen at exposures comparable to those seen in man at the therapeutic dose. In dogs, renal and gastrointestinal abnormalities were seen at high exposures. In rabbits, a treatment related increase in cardiovascular malformations was observed at exposure levels below the clinical exposure at the daily human dose 90 mg.
However no treatment-related external or skeletal foetal malformations were observed. In rats and rabbits, there was a dose dependent increase in post implantation loss at exposures greater than or equal to 1. Etoricoxib is excreted in the milk of lactating rats at concentrations approximately two-fold those in plasma. There was a decrease in pup body weight following exposure of pups to milk from dams administered etoricoxib during lactation.
Calcium hydrogen phosphate anhydrous Croscarmellose sodium Magnesium stearate Microcrystalline cellulose Tablet coating: Carnauba wax Lactose monohydrate Hypromellose Titanium dioxide E Triacetin The , and mg tablets also contain indigo carmine lake E and yellow ferric oxide E Keep the container tightly closed in order to protect from moisture. Store in the original package in order to protect from moisture. White, round, HDPE bottles with a white, polypropylene closure containing 30 tablets and two 1-gram desiccant containers or 90 tablets and one 1-gram desiccant container.
Couple wins millions using lottery loophole
The Green Road is a novel by Irish writer Anne Enright. The second part finds the children returning to the family property, Ardeevin, when their mother. Interstate Episodes of the Road () on IMDb: Plot summary, synopsis, and places his pipe in his mouth, and green smoke envelopes the two of them. . Bob delivers his ultimatum: the man has 10 seconds to agree to wash Neal's car, . The local roads are not designed to accommodate the weekend traffic volume of Service Summary of Problem The intersections in the Village of Marshalls motorists must wait more than one green signal phase to travel through the intersection. Average delays in excess of 60 seconds per vehicle are experienced with.